View in EDS

Autoantibodies neutralizing type I interferons remain a significant risk factor for critical COVID-19 pneumonia in vaccinated patients.

Saved in:
Bibliographic Details
Title: Autoantibodies neutralizing type I interferons remain a significant risk factor for critical COVID-19 pneumonia in vaccinated patients.
Authors: Antolí A; Internal Medicine Department, Hospital Universitari de Bellvitge. L'Hospitalet de Llobregat, Barcelona, Spain; Adult Primary Immunodeficiency Unit (UFIPA), Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain; Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain; Faculty of Medicine and Health Sciences, Universitat de Barcelona, Barcelona, Spain., Gómez-Vázquez JL; Adult Primary Immunodeficiency Unit (UFIPA), Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain; Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain; Faculty of Medicine and Health Sciences, Universitat de Barcelona, Barcelona, Spain., Sierra-Fortuny A; Adult Primary Immunodeficiency Unit (UFIPA), Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain; Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain., Bermudez-Carre C; Adult Primary Immunodeficiency Unit (UFIPA), Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain; Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain., Framil M; Adult Primary Immunodeficiency Unit (UFIPA), Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain; Faculty of Medicine and Health Sciences, Universitat de Barcelona, Barcelona, Spain; Immunology Department, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain., Creus-Bachiller E; Hereditary Cancer Program, Catalan Institute of Oncology, ICO, Hospitalet de Llobregat, Barcelona, Spain; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain; Biomedical Research Centre in Cancer Network (CIBERONC), Carlos III Health Institute, Madrid, Spain., Viana-Errasti J; Hereditary Cancer Program, Catalan Institute of Oncology, ICO, Hospitalet de Llobregat, Barcelona, Spain; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain., Rofes P; Hereditary Cancer Program, Catalan Institute of Oncology, ICO, Hospitalet de Llobregat, Barcelona, Spain; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain; Biomedical Research Centre in Cancer Network (CIBERONC), Carlos III Health Institute, Madrid, Spain., Rocamora-Blanch G; Internal Medicine Department, Hospital Universitari de Bellvitge. L'Hospitalet de Llobregat, Barcelona, Spain; Adult Primary Immunodeficiency Unit (UFIPA), Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain; Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain; Faculty of Medicine and Health Sciences, Universitat de Barcelona, Barcelona, Spain., Hidalgo-Peña L; Internal Medicine Department, Hospital Universitari de Bellvitge. L'Hospitalet de Llobregat, Barcelona, Spain; Adult Primary Immunodeficiency Unit (UFIPA), Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain., García-Serrano L; Adult Primary Immunodeficiency Unit (UFIPA), Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain; Immunology Department, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain., Rigo-Bonnin R; Clinical Laboratory Department, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain., Feliubadaló L; Hereditary Cancer Program, Catalan Institute of Oncology, ICO, Hospitalet de Llobregat, Barcelona, Spain; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain; Biomedical Research Centre in Cancer Network (CIBERONC), Carlos III Health Institute, Madrid, Spain., Del Valle J; Hereditary Cancer Program, Catalan Institute of Oncology, ICO, Hospitalet de Llobregat, Barcelona, Spain; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain; Biomedical Research Centre in Cancer Network (CIBERONC), Carlos III Health Institute, Madrid, Spain., Calatayud L; Microbiology Department, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain; Biomedical Research Centre in Respiratory Diseases Network (CIBERES), Carlos III Health Institute, Madrid, Spain., Morandeira F; Adult Primary Immunodeficiency Unit (UFIPA), Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain; Immunology Department, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain., Lázaro C; Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain; Faculty of Medicine and Health Sciences, Universitat de Barcelona, Barcelona, Spain; Hereditary Cancer Program, Catalan Institute of Oncology, ICO, Hospitalet de Llobregat, Barcelona, Spain; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain; Biomedical Research Centre in Cancer Network (CIBERONC), Carlos III Health Institute, Madrid, Spain., Solanich X; Internal Medicine Department, Hospital Universitari de Bellvitge. L'Hospitalet de Llobregat, Barcelona, Spain; Adult Primary Immunodeficiency Unit (UFIPA), Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain; Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain; Faculty of Medicine and Health Sciences, Universitat de Barcelona, Barcelona, Spain; Biomedical Research Centre in Obesity and Nutrition Physiopathology Network (CIBEROBN), Carlos III Health Institute, Madrid, Spain. Electronic address: xsolanich@bellvitgehospital.cat.
Source: Clinical immunology (Orlando, Fla.) [Clin Immunol] 2025 Jul; Vol. 276, pp. 110491. Date of Electronic Publication: 2025 Apr 02.
Publication Type: Journal Article
Journal Info: Publisher: Academic Press Country of Publication: United States NLM ID: 100883537 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1521-7035 (Electronic) Linking ISSN: 15216616 NLM ISO Abbreviation: Clin Immunol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40185298
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Autoantibodies neutralizing type I interferons remain a significant risk factor for critical COVID-19 pneumonia in vaccinated patients.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Antolí+A%22">Antolí A</searchLink>; Internal Medicine Department, Hospital Universitari de Bellvitge. L'Hospitalet de Llobregat, Barcelona, Spain; Adult Primary Immunodeficiency Unit (UFIPA), Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain; Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain; Faculty of Medicine and Health Sciences, Universitat de Barcelona, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Gómez-Vázquez+JL%22">Gómez-Vázquez JL</searchLink>; Adult Primary Immunodeficiency Unit (UFIPA), Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain; Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain; Faculty of Medicine and Health Sciences, Universitat de Barcelona, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Sierra-Fortuny+A%22">Sierra-Fortuny A</searchLink>; Adult Primary Immunodeficiency Unit (UFIPA), Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain; Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Bermudez-Carre+C%22">Bermudez-Carre C</searchLink>; Adult Primary Immunodeficiency Unit (UFIPA), Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain; Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Framil+M%22">Framil M</searchLink>; Adult Primary Immunodeficiency Unit (UFIPA), Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain; Faculty of Medicine and Health Sciences, Universitat de Barcelona, Barcelona, Spain; Immunology Department, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Creus-Bachiller+E%22">Creus-Bachiller E</searchLink>; Hereditary Cancer Program, Catalan Institute of Oncology, ICO, Hospitalet de Llobregat, Barcelona, Spain; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain; Biomedical Research Centre in Cancer Network (CIBERONC), Carlos III Health Institute, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Viana-Errasti+J%22">Viana-Errasti J</searchLink>; Hereditary Cancer Program, Catalan Institute of Oncology, ICO, Hospitalet de Llobregat, Barcelona, Spain; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Rofes+P%22">Rofes P</searchLink>; Hereditary Cancer Program, Catalan Institute of Oncology, ICO, Hospitalet de Llobregat, Barcelona, Spain; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain; Biomedical Research Centre in Cancer Network (CIBERONC), Carlos III Health Institute, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Rocamora-Blanch+G%22">Rocamora-Blanch G</searchLink>; Internal Medicine Department, Hospital Universitari de Bellvitge. L'Hospitalet de Llobregat, Barcelona, Spain; Adult Primary Immunodeficiency Unit (UFIPA), Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain; Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain; Faculty of Medicine and Health Sciences, Universitat de Barcelona, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Hidalgo-Peña+L%22">Hidalgo-Peña L</searchLink>; Internal Medicine Department, Hospital Universitari de Bellvitge. L'Hospitalet de Llobregat, Barcelona, Spain; Adult Primary Immunodeficiency Unit (UFIPA), Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22García-Serrano+L%22">García-Serrano L</searchLink>; Adult Primary Immunodeficiency Unit (UFIPA), Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain; Immunology Department, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Rigo-Bonnin+R%22">Rigo-Bonnin R</searchLink>; Clinical Laboratory Department, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Feliubadaló+L%22">Feliubadaló L</searchLink>; Hereditary Cancer Program, Catalan Institute of Oncology, ICO, Hospitalet de Llobregat, Barcelona, Spain; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain; Biomedical Research Centre in Cancer Network (CIBERONC), Carlos III Health Institute, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Del+Valle+J%22">Del Valle J</searchLink>; Hereditary Cancer Program, Catalan Institute of Oncology, ICO, Hospitalet de Llobregat, Barcelona, Spain; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain; Biomedical Research Centre in Cancer Network (CIBERONC), Carlos III Health Institute, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Calatayud+L%22">Calatayud L</searchLink>; Microbiology Department, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain; Biomedical Research Centre in Respiratory Diseases Network (CIBERES), Carlos III Health Institute, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Morandeira+F%22">Morandeira F</searchLink>; Adult Primary Immunodeficiency Unit (UFIPA), Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain; Immunology Department, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Lázaro+C%22">Lázaro C</searchLink>; Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain; Faculty of Medicine and Health Sciences, Universitat de Barcelona, Barcelona, Spain; Hereditary Cancer Program, Catalan Institute of Oncology, ICO, Hospitalet de Llobregat, Barcelona, Spain; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain; Biomedical Research Centre in Cancer Network (CIBERONC), Carlos III Health Institute, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Solanich+X%22">Solanich X</searchLink>; Internal Medicine Department, Hospital Universitari de Bellvitge. L'Hospitalet de Llobregat, Barcelona, Spain; Adult Primary Immunodeficiency Unit (UFIPA), Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain; Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain; Faculty of Medicine and Health Sciences, Universitat de Barcelona, Barcelona, Spain; Biomedical Research Centre in Obesity and Nutrition Physiopathology Network (CIBEROBN), Carlos III Health Institute, Madrid, Spain. Electronic address: xsolanich@bellvitgehospital.cat.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22100883537%22">Clinical immunology (Orlando, Fla.)</searchLink> [Clin Immunol] 2025 Jul; Vol. 276, pp. 110491. <i>Date of Electronic Publication: </i>2025 Apr 02.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Academic+Press%22">Academic Press </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>100883537 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1521-7035 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2215216616%22">15216616 </searchLink><i>NLM ISO Abbreviation: </i>Clin Immunol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40185298
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.clim.2025.110491
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 110491
    Titles:
      – TitleFull: Autoantibodies neutralizing type I interferons remain a significant risk factor for critical COVID-19 pneumonia in vaccinated patients.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Antolí A
      – PersonEntity:
          Name:
            NameFull: Gómez-Vázquez JL
      – PersonEntity:
          Name:
            NameFull: Sierra-Fortuny A
      – PersonEntity:
          Name:
            NameFull: Bermudez-Carre C
      – PersonEntity:
          Name:
            NameFull: Framil M
      – PersonEntity:
          Name:
            NameFull: Creus-Bachiller E
      – PersonEntity:
          Name:
            NameFull: Viana-Errasti J
      – PersonEntity:
          Name:
            NameFull: Rofes P
      – PersonEntity:
          Name:
            NameFull: Rocamora-Blanch G
      – PersonEntity:
          Name:
            NameFull: Hidalgo-Peña L
      – PersonEntity:
          Name:
            NameFull: García-Serrano L
      – PersonEntity:
          Name:
            NameFull: Rigo-Bonnin R
      – PersonEntity:
          Name:
            NameFull: Feliubadaló L
      – PersonEntity:
          Name:
            NameFull: Del Valle J
      – PersonEntity:
          Name:
            NameFull: Calatayud L
      – PersonEntity:
          Name:
            NameFull: Morandeira F
      – PersonEntity:
          Name:
            NameFull: Lázaro C
      – PersonEntity:
          Name:
            NameFull: Solanich X
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 07
              Text: 2025 Jul
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1521-7035
          Numbering:
            – Type: volume
              Value: 276
          Titles:
            – TitleFull: Clinical immunology (Orlando, Fla.)
              Type: main
ResultId 1